{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:35:42Z","timestamp":1790073342557,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007787","name":"National Research Centre","doi-asserted-by":"publisher","award":["13060103"],"award-info":[{"award-number":["13060103"]}],"id":[{"id":"10.13039\/100007787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmc.2025.118370","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T15:12:52Z","timestamp":1756134772000},"page":"118370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Hybrid molecules of ibuprofen and piperidone: a rational approach toward anti-cancer drug development"],"prefix":"10.1016","volume":"130","author":[{"given":"Siva S.","family":"Panda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.F.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo S.","family":"Chagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Emami Naeini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Morsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FaithAnn A.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunj Bihari","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido F.","family":"Verbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Baban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthusamy","family":"Thangaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal L.","family":"Lokeshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel S.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118370_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesm","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2025.118370_bb0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","article-title":"Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets","volume":"9","author":"Zhang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118370_bb0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118370_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","article-title":"Targeting metastatic cancer","volume":"27","author":"Ganesh","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2025.118370_bb0025","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2025.118370_bb0030","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","article-title":"Research and development spending to bring a single cancer drug to market and revenues after approval","volume":"177","author":"Prasad","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.bmc.2025.118370_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41698-022-00343-y","article-title":"Precision medicine: affording the successes of science","volume":"7","author":"Lu","year":"2023","journal-title":"npj precis Onc"},{"key":"10.1016\/j.bmc.2025.118370_bb0040","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2025.118370_bb0045","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118370_bb0050","doi-asserted-by":"crossref","unstructured":"W. Tang, Z, Chen, W. Zhang, Y. Cheng, B. Zhang, F. Wu, Q. Wang, S. Wang, D. Rong, F.P. Reiter, E.N. De Toni, X. Wang, The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects, Signal Transduct Target Ther 5 (2020) 87, doi:https:\/\/doi.org\/10.1038\/s41698-022-00343-y.","DOI":"10.1038\/s41392-020-0187-x"},{"key":"10.1016\/j.bmc.2025.118370_bb0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.bmc.2025.118370_bb0060","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1021\/acs.jmedchem.1c00048","article-title":"Sustainable drug discovery of multi-target-directed ligands for Alzheimer\u2019s disease","volume":"64","author":"Rossi","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0065","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.drudis.2020.07.004","article-title":"Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors","volume":"25","author":"Ma","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2025.118370_bb0070","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bmc.2025.118370_bb0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118370_bb0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/cancers15030692","article-title":"Use of nonsteroidal anti-inflammatory drugs and risk of breast cancer: evidence from a general female population and a mammographic screening cohort in Sweden","volume":"15","author":"Hu","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2025.118370_bb0085","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/dji140","article-title":"Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status","volume":"97","author":"Marshall","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bmc.2025.118370_bb0090","first-page":"1","article-title":"Role of nonsteroidal anti-inflammatory drugs (nsaids) in cancer prevention and cancer promotion","volume":"2019","author":"Wong","year":"2019","journal-title":"Adv Pharmacol Sci"},{"key":"10.1016\/j.bmc.2025.118370_bb0095","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/1078-0432.CCR-04-1696","article-title":"Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer","volume":"11","author":"Yao","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118370_bb0100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13058-020-01343-1","article-title":"Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women","volume":"22","author":"Cairat","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.bmc.2025.118370_bb0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000452315","article-title":"The role of NSAIDs in breast cancer prevention and relapse: current evidence and future perspectives","volume":"11","author":"Moris","year":"2016","journal-title":"Breast Care"},{"key":"10.1016\/j.bmc.2025.118370_bb0110","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.3390\/cancers16173108","article-title":"Curcumin-dichloroacetate hybrid molecule as an antitumor oral drug against multidrug-resistant advanced bladder cancers","volume":"16","author":"Gupta","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2025.118370_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400376","article-title":"Ursolic acid conjugates: a new frontier in anticancer drug development","volume":"25","author":"Bokhtia","year":"2024","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bmc.2025.118370_bb0120","doi-asserted-by":"crossref","unstructured":"RM. Bokhtia, S.S. Panda, A.S. Girgis, N. Samir, M.F. Said, A. Abdelnaser, S. Nasr, M.S. Bekheit, A.S. Dawood, H. Sharma, M. Wade, S.K. Sharma, A.M. Ghanim, New NSAID conjugates as potent and selective COX-2 inhibitors: synthesis, molecular modeling and biological investigation. Molecules 28 (2023) 1945, doi:https:\/\/doi.org\/10.3390\/molecules28041945.","DOI":"10.3390\/molecules28041945"},{"key":"10.1016\/j.bmc.2025.118370_bb0125","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/ph15040451","article-title":"Design, synthesis, and molecular docking studies of curcumin hybrid conjugates as potential therapeutics for breast cancer","volume":"15","author":"Panda","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmc.2025.118370_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202201406","article-title":"Novel curcumin mimics: design, synthesis, biological properties and computational studies of piperidone-piperazine conjugates","volume":"7","author":"Youssef","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bmc.2025.118370_bb0135","doi-asserted-by":"crossref","unstructured":"A.M. Srour, S.S Panda, A. Mostafa, W. Fayad, M.A. El-Manawaty, A.A.F. Soliman, Y. Moatasim, A. El Taweel, M.F. Abdelhameed, M.S. Bekheit, A.S. Girgis, Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties. Bioorg Chem 117 (2021) 105466, doi:https:\/\/doi.org\/10.1016\/j.bioorg.2021.105466.","DOI":"10.1016\/j.bioorg.2021.105466"},{"key":"10.1016\/j.bmc.2025.118370_bb0140","doi-asserted-by":"crossref","first-page":"33761","DOI":"10.1039\/C9RA05661K","article-title":"Synthesis, human topoisomerase II\u03b1 inhibitory properties and molecular modeling studies of antiproliferative curcumin mimics","volume":"9","author":"Fawzy","year":"2019","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2025.118370_bb0145","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2174\/1871520619666190408131639","article-title":"Synthesis and molecular modeling studies of anti-proliferative curcumin mimics","volume":"19","author":"Fawzy","year":"2019","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126878","article-title":"Novel hybrid molecules of 3,5-bis(benzylidene)-4-piperidones and dichloroacetic acid which demonstrate potent tumour-selective cytotoxicity","volume":"30","author":"Hossain","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118370_bb0155","first-page":"1369","article-title":"Synthesis of new ibuprofen hybrid conjugates as potential anti-inflammatory and analgesic agents, future","volume":"12","author":"Panda","year":"2020","journal-title":"Med Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200164","article-title":"Development of isatin-based Schiff bases targeting VEGFR-2 inhibition: synthesis, characterization, antiproliferative properties, and QSAR studies","volume":"17","author":"Seliem","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2025.118370_bb0170","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.intimp.2011.11.015","article-title":"Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo","volume":"12","author":"Babaei","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bmc.2025.118370_bb0175","first-page":"81e94","article-title":"Current state of animal (mouse) modeling in melanoma research. Supplementary issue: animal models of cancer biology","volume":"8","author":"Kuzu","year":"2015","journal-title":"Cancer Growth Metastasis"},{"key":"10.1016\/j.bmc.2025.118370_bb0180","first-page":"209","article-title":"Epigenetic mechanisms involved in melanoma pathogenesis and chemo resistance","volume":"3","author":"Martinez-Cardus","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.bmc.2025.118370_bb0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jss.2018.08.055","article-title":"Cannabinoids as a potential new and novel treatment for melanoma: a pilot study in a murine model","volume":"235","author":"Simmerman","year":"2019","journal-title":"J Surg Res"},{"key":"10.1016\/j.bmc.2025.118370_bb0190","doi-asserted-by":"crossref","first-page":"10147","DOI":"10.1021\/acs.jmedchem.6b00900","article-title":"Discovery of novel spiro[3H-indole-3,2\u2032-pyrrolidin]-2(1H)-one compounds as chemically stable and orally active inhibitors of the MDM2\u2013p53 interaction","volume":"59","author":"Gollner","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41061-016-0089-0","article-title":"Spiro-oxindoles as a promising class of small molecule inhibitors of p53\u2013MDM2 interaction useful in targeted cancer therapy","volume":"375","author":"Gupta","year":"2017","journal-title":"Top Curr Chem (Z)"},{"key":"10.1016\/j.bmc.2025.118370_bb0200","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/ph18020274","article-title":"The therapeutic potential of Spirooxindoles in Cancer: a focus on p53\u2013MDM2 modulation","volume":"18","author":"Girgis","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmc.2025.118370_bb0205","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1021\/jm300969t","article-title":"Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction","volume":"55","author":"Zhuang","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0210","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.3390\/molecules27123721","article-title":"Synthesis and biological evaluation of novel synthetic indolone derivatives as anti-tumor agents targeting p53-MDM2 and p53-MDMX","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118370_bb0215","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1021\/jm401753e","article-title":"Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development","volume":"57","author":"Sun","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/13543776.2019.1582645","article-title":"A therapeutic patent overview of MDM2\/X-targeted therapies (2014\u20132018)","volume":"29","author":"Skalniak","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2025.118370_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.09.044","article-title":"The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy","volume":"159","author":"Liao","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0230","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1021\/jm300354j","article-title":"Structure-based design of novel inhibitors of the MDM2\u2013p53 interaction","volume":"14","author":"Rew","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0235","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41419-018-0825-1","article-title":"Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells","volume":"9","author":"Her","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2025.118370_bb0240","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1016\/j.bmcl.2014.06.073","article-title":"Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein\u2013protein interaction","volume":"24","author":"Wang","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118370_bb0245","doi-asserted-by":"crossref","first-page":"28609","DOI":"10.1074\/jbc.M703796200","article-title":"EF24 induces G2\/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression","volume":"282","author":"Selvendiran","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0265","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cca.2021.11.005","article-title":"Evaluation of ER, PR and HER2 markers by flow cytometry for breast cancer diagnosis and prognosis","volume":"523","author":"Wopereis","year":"2021","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.bmc.2025.118370_bb0270","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","article-title":"Analysis of apoptosis by propidium iodide staining and flow cytometry","volume":"1","author":"Riccardi","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bmc.2025.118370_bb0275","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41598-024-82005-6","article-title":"Design and synthesis of antiproliferative 2-oxoindolin-3-ylidenes incorporating urea function with potential VEGFR-2 inhibitory properties","volume":"15","author":"Aboshouk","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118370_bb0285","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/s41598-025-85588-w","article-title":"Curcumin mimics of potential chemoprevention with NQO1 induction properties","volume":"15","author":"Aboshouk","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118370_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2011.11.034","article-title":"Computer-assisted rational design, synthesis, and bioassay of non-steroidal anti-inflammatory agents","volume":"50","author":"Girgis","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118370_bb0300","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118370_bb0305","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1021\/ja401184g","article-title":"Stochastic voyages into uncharted chemical space produce a representative library of all possible drug-like compounds","volume":"135","author":"Virshup","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2025.118370_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202200116","article-title":"Chemical multiverse: an expanded view of chemical space","volume":"41","author":"Medina-Franco","year":"2022","journal-title":"Mol Inform"},{"key":"10.1016\/j.bmc.2025.118370_bb0315","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: a webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2025.118370_bb0320","doi-asserted-by":"crossref","first-page":"12869","DOI":"10.1111\/jcmm.15883","article-title":"Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome","volume":"24","author":"Salles","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bmc.2025.118370_bb0325","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1535-7163.MCT-23-0806","article-title":"Targeting Chemoresistance in advanced bladder cancers with a novel adjuvant strategy","volume":"23","author":"Seremak","year":"2024","journal-title":"Mol Cancer Ther"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:17:51Z","timestamp":1772878671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625003116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"alternative-id":["S0968089625003116"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118370","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hybrid molecules of ibuprofen and piperidone: a rational approach toward anti-cancer drug development","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118370"}}